TEC-话题@MedSci

#TEC#

484篇内容 | 2468人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1652512, encodeId=e6b31652512ff, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, objectTitle=2022年1月26日简报：奥密克戎病例约占全美新病例的99.9%；奥密克戎亚型突变株BA.2的病例正在增加；辉瑞和BioNTech就针对奥密克戎的新冠疫苗启动临床试验, objectType=article, longId=294735, objectId=a9db294e35e9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a9db294e35e9, replyNumber=0, likeNumber=28, createdTime=2022-10-01, rootId=0, userName=shock_melon, userId=852f24292001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a9db294e35e9, moduleTitle=2022年1月26日简报：奥密克戎病例约占全美新病例的99.9%；奥密克戎亚型突变株BA.2的病例正在增加；辉瑞和BioNTech就针对奥密克戎的新冠疫苗启动临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a9db294e35e9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652539, encodeId=303a1652539e0, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, objectTitle=Skin Res Technol：高频超声鉴别高危基底细胞癌和皮肤鳞状细胞癌, objectType=article, longId=738388, objectId=9d54e383880e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9d54e383880e, replyNumber=0, likeNumber=54, createdTime=2023-07-23, rootId=0, userName=shock_melon, userId=852f24292001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9d54e383880e, moduleTitle=Skin Res Technol：高频超声鉴别高危基底细胞癌和皮肤鳞状细胞癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9d54e383880e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652535, encodeId=cc411652535f8, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, objectTitle=辉瑞/BioNTech向FDA和EMA提交二价奥密克戎特异性mRNA疫苗上市申请, objectType=article, longId=736670, objectId=313be36670fc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=313be36670fc, replyNumber=0, likeNumber=55, createdTime=2023-01-23, rootId=0, userName=shock_melon, userId=852f24292001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=313be36670fc, moduleTitle=辉瑞/BioNTech向FDA和EMA提交二价奥密克戎特异性mRNA疫苗上市申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=313be36670fc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652527, encodeId=37ee165252e49, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, objectTitle=Trastuzumab Deruxtecan治疗HER2阳性乳腺癌效果优于trastuzumab emtansine, objectType=article, longId=725405, objectId=f586e25405ed, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f586e25405ed, replyNumber=0, likeNumber=44, createdTime=2023-03-13, rootId=0, userName=shock_melon, userId=852f24292001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f586e25405ed, moduleTitle=Trastuzumab Deruxtecan治疗HER2阳性乳腺癌效果优于trastuzumab emtansine, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f586e25405ed)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652518, encodeId=08ae165251846, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, objectTitle=Kaneka Eurogentec宣布一批次成功量产25克mRNA, objectType=article, longId=299514, objectId=032a29951496, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=032a29951496, replyNumber=0, likeNumber=39, createdTime=2022-07-10, rootId=0, userName=shock_melon, userId=852f24292001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=032a29951496, moduleTitle=Kaneka Eurogentec宣布一批次成功量产25克mRNA, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=032a29951496)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652498, encodeId=4e8516524982b, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, objectTitle=TECHNOL CANCER RES T：这个MRI指标，竟可“剧透”乳腺癌新辅助化疗效果！, objectType=article, longId=217552, objectId=acb721e552f5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=acb721e552f5, replyNumber=0, likeNumber=62, createdTime=2022-03-14, rootId=0, userName=shock_melon, userId=852f24292001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=acb721e552f5, moduleTitle=TECHNOL CANCER RES T：这个MRI指标，竟可“剧透”乳腺癌新辅助化疗效果！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=acb721e552f5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652502, encodeId=5a2316525023e, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, objectTitle=欧盟人用药品委员会 (CHMP) 对sacituzumab govitecan单药治疗三阴性乳腺癌 (TNBC) 持积极意见, objectType=article, longId=218739, objectId=cba7218e390b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cba7218e390b, replyNumber=0, likeNumber=52, createdTime=2021-12-09, rootId=0, userName=shock_melon, userId=852f24292001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cba7218e390b, moduleTitle=欧盟人用药品委员会 (CHMP) 对sacituzumab govitecan单药治疗三阴性乳腺癌 (TNBC) 持积极意见, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cba7218e390b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652495, encodeId=339216524955a, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, objectTitle=美国FDA全面批准辉瑞BioNTech新冠mRNA疫苗，美军将全员接种, objectType=article, longId=216255, objectId=a27c21625501, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a27c21625501, replyNumber=0, likeNumber=39, createdTime=2021-09-18, rootId=0, userName=shock_melon, userId=852f24292001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a27c21625501, moduleTitle=美国FDA全面批准辉瑞BioNTech新冠mRNA疫苗，美军将全员接种, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a27c21625501)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652517, encodeId=c669165251eee, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, objectTitle=Mawi DNA Technologies获得两项ISO认证, objectType=article, longId=299040, objectId=84342990403a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=84342990403a, replyNumber=0, likeNumber=29, createdTime=2022-06-12, rootId=0, userName=shock_melon, userId=852f24292001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=84342990403a, moduleTitle=Mawi DNA Technologies获得两项ISO认证, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=84342990403a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652513, encodeId=a53f165251382, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, objectTitle=梅斯早读丨CDC：感染奥密克戎病例约占全美新病例的99.9%；辉瑞和BioNTech就针对奥密克戎的新冠疫苗启动临床试验, objectType=article, longId=294831, objectId=e368294831ab, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e368294831ab, replyNumber=0, likeNumber=34, createdTime=2022-08-05, rootId=0, userName=shock_melon, userId=852f24292001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e368294831ab, moduleTitle=梅斯早读丨CDC：感染奥密克戎病例约占全美新病例的99.9%；辉瑞和BioNTech就针对奥密克戎的新冠疫苗启动临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e368294831ab)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652511, encodeId=f9ad165251137, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, objectTitle=Nature Biotechnology：发现治疗白血病的新型免疫疗法, objectType=article, longId=291799, objectId=443f291e99a1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=443f291e99a1, replyNumber=0, likeNumber=33, createdTime=2022-05-13, rootId=0, userName=shock_melon, userId=852f24292001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=443f291e99a1, moduleTitle=Nature Biotechnology：发现治疗白血病的新型免疫疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=443f291e99a1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652508, encodeId=bde6165250869, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, objectTitle=早期数据显示 Omicron 部分避开了辉瑞和 BioNTech COVID-19 疫苗, objectType=article, longId=221777, objectId=6a71221e773b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6a71221e773b, replyNumber=0, likeNumber=43, createdTime=2022-01-14, rootId=0, userName=shock_melon, userId=852f24292001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6a71221e773b, moduleTitle=早期数据显示 Omicron 部分避开了辉瑞和 BioNTech COVID-19 疫苗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6a71221e773b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652520, encodeId=98541652520dd, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, objectTitle=Nature Biotechnology：瞒天过海，给细菌穿上“隐身衣”，让它们绕过免疫系统去攻击癌细胞, objectType=article, longId=301267, objectId=f87030126e8b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f87030126e8b, replyNumber=0, likeNumber=46, createdTime=2022-09-21, rootId=0, userName=shock_melon, userId=852f24292001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f87030126e8b, moduleTitle=Nature Biotechnology：瞒天过海，给细菌穿上“隐身衣”，让它们绕过免疫系统去攻击癌细胞, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f87030126e8b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652525, encodeId=2d251652525c1, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, objectTitle=J Nanobiotechnology：多功能复合水凝胶作为内源性和外源性协同调节剂提高银屑病的疗效, objectType=article, longId=724095, objectId=76d0e24095b8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=76d0e24095b8, replyNumber=0, likeNumber=33, createdTime=2022-10-09, rootId=0, userName=shock_melon, userId=852f24292001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=76d0e24095b8, moduleTitle=J Nanobiotechnology：多功能复合水凝胶作为内源性和外源性协同调节剂提高银屑病的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=76d0e24095b8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652523, encodeId=ae28165252335, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, objectTitle=Alvotech和STADA与艾伯维解决欧洲专利纠纷，为Humira®的无柠檬酸盐、高浓度生物仿制药HUKYNDRA®(AVT02)上市铺平道路, objectType=article, longId=723787, objectId=0b3be23787cf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0b3be23787cf, replyNumber=0, likeNumber=44, createdTime=2022-07-11, rootId=0, userName=shock_melon, userId=852f24292001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0b3be23787cf, moduleTitle=Alvotech和STADA与艾伯维解决欧洲专利纠纷，为Humira®的无柠檬酸盐、高浓度生物仿制药HUKYNDRA®(AVT02)上市铺平道路, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0b3be23787cf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652501, encodeId=006016525018e, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, objectTitle=BioNTech基于mRNA技术的癌症疫苗开启二期临床试验，新冠疫苗与药物市场格局恐生变, objectType=article, longId=218235, objectId=e8f2218235c1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e8f2218235c1, replyNumber=0, likeNumber=55, createdTime=2022-02-07, rootId=0, userName=shock_melon, userId=852f24292001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e8f2218235c1, moduleTitle=BioNTech基于mRNA技术的癌症疫苗开启二期临床试验，新冠疫苗与药物市场格局恐生变, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e8f2218235c1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652529, encodeId=e5831652529cf, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, objectTitle=JAMA Oncol：Etirinotecan pegol vs 化疗治疗有脑转移的乳腺癌的预后, objectType=article, longId=727101, objectId=5187e27101bb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5187e27101bb, replyNumber=0, likeNumber=50, createdTime=2022-12-31, rootId=0, userName=shock_melon, userId=852f24292001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5187e27101bb, moduleTitle=JAMA Oncol：Etirinotecan pegol vs 化疗治疗有脑转移的乳腺癌的预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5187e27101bb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652491, encodeId=5e88165249154, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, objectTitle=BioNTechQ2财报亮眼，4项临床试验针对Delta变种, objectType=article, longId=215544, objectId=3725215544f1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3725215544f1, replyNumber=0, likeNumber=41, createdTime=2022-03-02, rootId=0, userName=shock_melon, userId=852f24292001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3725215544f1, moduleTitle=BioNTechQ2财报亮眼，4项临床试验针对Delta变种, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3725215544f1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652522, encodeId=64bc1652522b4, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, objectTitle=Nature Biotechnology：斯坦福/牛津纳米孔/谷歌/英伟达合作，开发超快速纳米孔测序，7小时发现致病基因突变, objectType=article, longId=301958, objectId=3051301958c7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3051301958c7, replyNumber=0, likeNumber=33, createdTime=2022-08-05, rootId=0, userName=shock_melon, userId=852f24292001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3051301958c7, moduleTitle=Nature Biotechnology：斯坦福/牛津纳米孔/谷歌/英伟达合作，开发超快速纳米孔测序，7小时发现致病基因突变, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3051301958c7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652514, encodeId=42fe165251417, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, objectTitle=Alvotech与BiosanaPharma达成全球独家许可协议，共同开发Xolair®（奥马珠单抗）的拟议生物仿制药(AVT23), objectType=article, longId=295364, objectId=dce229536434, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dce229536434, replyNumber=0, likeNumber=49, createdTime=2023-01-07, rootId=0, userName=shock_melon, userId=852f24292001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dce229536434, moduleTitle=Alvotech与BiosanaPharma达成全球独家许可协议，共同开发Xolair®（奥马珠单抗）的拟议生物仿制药(AVT23), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dce229536434)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

TEC

2020-05-29

shock_melon (审核中...)

前往app查看评论内容

#TEC#

2022年1月26日简报：奥密克戎病例约占全美新病例的99.9%；奥密克戎亚型突变株BA.2的病例正在增加；辉瑞和BioNTech就针对奥密克戎的新冠疫苗启动临床试验

2022-10-01

shock_melon (审核中...)

前往app查看评论内容

#TEC#

Skin Res Technol：高频超声鉴别高危基底细胞癌和皮肤鳞状细胞癌

2023-07-23

shock_melon (审核中...)

前往app查看评论内容

#TEC#

辉瑞/BioNTech向FDA和EMA提交二价奥密克戎特异性mRNA疫苗上市申请

2023-01-23

shock_melon (审核中...)

前往app查看评论内容

#TEC#

Trastuzumab Deruxtecan治疗HER2阳性乳腺癌效果优于trastuzumab emtansine

2023-03-13

shock_melon (审核中...)

前往app查看评论内容

#TEC#

Kaneka Eurogentec宣布一批次成功量产25克mRNA

2022-07-10

shock_melon (审核中...)

前往app查看评论内容

#TEC#

TECHNOL CANCER RES T：这个MRI指标，竟可“剧透”乳腺癌新辅助化疗效果！

2022-03-14

shock_melon (审核中...)

前往app查看评论内容

#TEC#

欧盟人用药品委员会 (CHMP) 对sacituzumab govitecan单药治疗三阴性乳腺癌 (TNBC) 持积极意见

2021-12-09

shock_melon (审核中...)

前往app查看评论内容

#TEC#

美国FDA全面批准辉瑞BioNTech新冠mRNA疫苗，美军将全员接种

2021-09-18

shock_melon (审核中...)

前往app查看评论内容

#TEC#

Mawi DNA Technologies获得两项ISO认证

2022-06-12

shock_melon (审核中...)

前往app查看评论内容

#TEC#

梅斯早读丨CDC：感染奥密克戎病例约占全美新病例的99.9%；辉瑞和BioNTech就针对奥密克戎的新冠疫苗启动临床试验

2022-08-05

shock_melon (审核中...)

前往app查看评论内容

#TEC#

Nature Biotechnology：发现治疗白血病的新型免疫疗法

2022-05-13

shock_melon (审核中...)

前往app查看评论内容

#TEC#

早期数据显示 Omicron 部分避开了辉瑞和 BioNTech COVID-19 疫苗

2022-01-14

shock_melon (审核中...)

前往app查看评论内容

#TEC#

Nature Biotechnology：瞒天过海，给细菌穿上“隐身衣”，让它们绕过免疫系统去攻击癌细胞

2022-09-21

shock_melon (审核中...)

前往app查看评论内容

#TEC#

J Nanobiotechnology：多功能复合水凝胶作为内源性和外源性协同调节剂提高银屑病的疗效

2022-10-09

shock_melon (审核中...)

前往app查看评论内容

#TEC#

Alvotech和STADA与艾伯维解决欧洲专利纠纷，为Humira®的无柠檬酸盐、高浓度生物仿制药HUKYNDRA®(AVT02)上市铺平道路

2022-07-11

shock_melon (审核中...)

前往app查看评论内容

#TEC#

BioNTech基于mRNA技术的癌症疫苗开启二期临床试验，新冠疫苗与药物市场格局恐生变

2022-02-07

shock_melon (审核中...)

前往app查看评论内容

#TEC#

JAMA Oncol：Etirinotecan pegol vs 化疗治疗有脑转移的乳腺癌的预后

2022-12-31

shock_melon (审核中...)

前往app查看评论内容

#TEC#

BioNTechQ2财报亮眼，4项临床试验针对Delta变种

2022-03-02

shock_melon (审核中...)

前往app查看评论内容

#TEC#

Nature Biotechnology：斯坦福/牛津纳米孔/谷歌/英伟达合作，开发超快速纳米孔测序，7小时发现致病基因突变

2022-08-05

shock_melon (审核中...)

前往app查看评论内容

#TEC#

Alvotech与BiosanaPharma达成全球独家许可协议，共同开发Xolair®（奥马珠单抗）的拟议生物仿制药(AVT23)

2023-01-07

科室
- - 订阅+
  - 更多科室
工具
服务